Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




First POC Hepatitis C RNA Test Enables Single-Visit Testing and Treatment

By LabMedica International staff writers
Posted on 28 Jun 2024

Hepatitis C, a liver infection caused by the hepatitis C virus (HCV), spreads through contact with the blood of an infected person. More...

While some individuals may experience a short-term illness, over half of those infected develop a chronic, long-term condition. In the United States, it is estimated that between 2.4 and 4 million people are living with hepatitis C. If untreated, the virus can lead to severe health issues, including liver cancer and liver failure. Until now, HCV testing has involved multiple steps, requiring patients to return for results and further tests, often resulting in missed diagnoses and treatment. Now, a breakthrough has been made with the introduction of the first point-of-care HCV test, which facilitates testing and treatment in a single visit for those at risk.

Developed by Cepheid (Sunnyvale, CA, USA), the Xpert HCV test eliminates the need to send samples to a central lab and can detect HCV RNA from a fingertip blood sample, delivering results within approximately one hour. The U.S. Food and Drug Administration has granted marketing authorization for the use of the Xpert HCV test alongside the GeneXpert Xpress System. This test is authorized for use in various settings under a CLIA (Clinical Laboratory Improvement Amendments) Certificate of Waiver, including substance use disorder treatment centers, correctional facilities, syringe service programs, physician's offices, emergency departments, and urgent care clinics. This significant development supports a test-and-treat approach, allowing individuals to be tested and, if they test positive for HCV RNA, to be connected to care and potentially begin treatment during the same healthcare visit.

"Despite the existence of a safe and highly effective oral cure for hepatitis C, many people do not know they have the disease due partly to the lack of availability of convenient, widespread testing options," said Jeff Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health. "Equipping health care providers with tools to diagnose and treat patients in the same visit can result in hundreds of thousands more hepatitis C patients being diagnosed and treated, preventing individual disease progression and additional spread of the virus."


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.